Hostname: page-component-669899f699-qzcqf Total loading time: 0 Render date: 2025-04-29T06:01:54.606Z Has data issue: false hasContentIssue false
  • English
  • Français

Positive and Negative Schizophrenic Symptoms and the Role of Dopamine

Published online by Cambridge University Press:  29 January 2018

T. J. Crow
T. J. Crow*
Affiliation:
Clinical Research Centre, Northwick Park, Harrow, Middlesex
Get access Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Discussion
Information
The British Journal of Psychiatry , Volume 137 , Issue 4 , October 1980 , pp. 383 - 386
Copyright
Copyright © Royal College of Psychiatrists, 1980 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Article purchase

Temporarily unavailable

References

Angrist, B., Rotrosen, J. & Gershon, S. (1980a) Responses to apomorphine, amphetamine and neuroleptics in schizophrenia subjects. Psychopharmacology, 67, 31–8.CrossRefGoogle Scholar
Angrist, B., Rotrosen, J. & Gershon, S. (1980b) Differential effects of amphetamine and neuroleptics on negative vs positive symptoms in schizophrenia. Psychopharmacology (in press).CrossRefGoogle Scholar
Bird, E. D., Crow, T. J., Iversen, L. L., Longden, A., Mackay, A. V. P., Riley, G. J. & Spokes, E. C. (1979) Dopamine and homovanillic acid concentrations in the post-mortem brain in schizophrenia. Journal of Physiology, 293, 36–7.Google ScholarPubMed
Bland, R. C. & Orn, H. (1980) Schizophrenia: Schneider's first-rank symptoms and outcome. British Journal of Psychiatry, 137, 63–8.Google Scholar
Brockington, I. F., Kendell, R. E. & Leff, J. P. (1978) Definitions of schizophrenia: concordance and prediction of outcome. Psychological Medicine, 8, 387–98.CrossRefGoogle ScholarPubMed
Chouinard, G. & Jones, B. D. (1978) Schizophrenia as dopamine-deficiency disease. Lancet, ii, 99–100.Google Scholar
Crow, T. J. (1980) Molecular pathology of schizophrenia: more than one disease process? British Medical Journal, 280, 66–8.CrossRefGoogle ScholarPubMed
Crow, T. J., Owen, F., Cross, A. J., Ferrier, I. N., Johnstone, E. C., McCreadie, R. G., Owens, D. G. C. & Poulter, M. (1980) Neurotransmitter enzymes and receptors in post-mortem brain in schizophrenia; evidence that an increase in D2 dopamine receptors is associated with the Type I syndrome. In press in Transmitter Biochemistry of Human Brain Tissue, edited by Usdin, E. and Riederer, P. Google Scholar
Gerlach, J. & Luhdorf, K. (1975) The effect of L-DOPA on young patients with simple schizophrenia treated with neuroleptic drugs. Psychopharmacology, 44, 105–10.CrossRefGoogle Scholar
Holden, J. M. C., Stock, M. J., Holden, U. P. & Itil, J. M. Profile patterns of therapy resistant schizophrenia. Manuscript submitted.Google Scholar
Hughes, J. S. & Little, J. C. (1967) An appraisal of the continuing practice of prescribing tranquillizing drugs for long-stay psychiatric patients. British Journal of Psychiatry, 113, 867–73.CrossRefGoogle ScholarPubMed
Kornetsky, C. (1976) Hyporesponsivity of chronic schizophrenic patients to dextroamphetamine. Archives of General Psychiatry, 33, 1425–8.Google Scholar
Johnstone, E. C., Crow, T. J., Frith, C. D., Carney, M. W. P. & Price, J. S. (1978a) Mechanism of the antipsychotic effect in the treatment of acute schizophrenia. Lancet, i, 848–51.Google Scholar
Johnstone, E. C., Crow, T. J., Frith, C. D., Stevens, M., Kreel, L. & Husband, J. (1978b) The dementia of dementia praecox. Acta Psychiatrica Scandinavica, 57, 305–24.Google Scholar
Lecrubier, Y., Puech, A. J., Widlocher, D. & Simon, P. (1980) Schizophrenia: a bipolar dopaminergic hypothesis. Abstract no. 390. Proceedings of the 12th CINP Congress, Göteborg. Progress in Neuro-psychopharmacology, supplement.Google Scholar
Lee, T., Seeman, P., Tourtellotte, W. W., Farley, I. J. & Hornykiewicz, O. (1978) Binding of 3H-apomorphine and 3H-neuroleptics in schizophrenic brains. Nature, 274, 897–900.Google Scholar
Letemendia, F. J. J. & Harris, A. D. (1967) Chlorpromazine and the untreated chronic schizophrenic: a long-term trial. British Journal of Psychiatry, 113, 950–8.CrossRefGoogle ScholarPubMed
Owen, F., Cross, A. J., Crow, T. J., Longden, A., Poulter, M. & Riley, G. J. (1978) Increased dopamine receptor sensitivity in schizophrenia. Lancet, ii, 223–5.Google Scholar
Owens, D. G. C. & Johnstone, E. C. (1980a) The disabilities of chronic schizophrenia—their nature and the factors contributing to their development. British Journal of Psychiatry, 136, 384–95.CrossRefGoogle Scholar
Owens, D. G. C. & Johnstone, E. C. (1980b) Neurological changes in a population of patients with chronic schizophrenia and their relationship to physical treatments. Acta Psychiatrica Scandinavica Supplement (in press).Google Scholar
Tsuang, M. T. (1980) Thirty to 40 year follow-up of schizophrenia: outcome and stability of diagnosis. Paper presented to the Schizophrenia Group, The Wellcome Trust, 22 May 1980.Google Scholar
Weinberger, D. R., Bigelow, L. B., Kleinman, J. E., Klein, S. T., Rosenblatt, J. E. & Wyatt, R. J. (1980) Cerebral ventricular enlargement in chronic schizophrenia associated with poor response to treatment. Archives of General Psychiatry, 37, 11–13.Google Scholar
Wing, J. K. (1978) Clinical concepts of schizophrenia. pp 1–30 in Schizophrenia: Towards a New Synthesis. Edited by Wing, J. K. Academic Press, London.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.